Letter

Mineworx Announces Sale of Cehegin Iron Ore Asset

Retrieved on: 
Monday, January 17, 2022 - 10:30am

EDMONTON, Alberta, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Mineworx Technologies Ltd., (the Company or Mineworx) (TSXV: MWX) (OTCQB: MWXRF) (FSE: YRS WKN: A2DSW3) announces that it has signed a letter of intent to sell the Cehegin Iron Ore Asset in Spain at a valuation of $20,000,000 CDN.

Key Points: 
  • EDMONTON, Alberta, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Mineworx Technologies Ltd., (the Company or Mineworx) (TSXV: MWX) (OTCQB: MWXRF) (FSE: YRS WKN: A2DSW3) announces that it has signed a letter of intent to sell the Cehegin Iron Ore Asset in Spain at a valuation of $20,000,000 CDN.
  • We believe the management of NewCo will bring great value and expertise in further monetizing the Cehegin asset moving forward.
  • The transaction is contingent on the completion of the due diligence process and the Company obtaining certain regulatory and shareholder approvals.
  • Mineworx is positioned for growth in CleanTech sector through the development and commercialization of its environmentally friendly processing technologies for the recovery of precious metals.

The Dark Side of Hotels and Airbnbs that You Don't Know About

Retrieved on: 
Sunday, January 16, 2022 - 11:55pm

We would like to share with you the dark side of hotels and Airbnbs that no one talks about.

Key Points: 
  • We would like to share with you the dark side of hotels and Airbnbs that no one talks about.
  • Normally, when someone stays at a hotel or Airbnb, they tend to feel pretty safe and comfortable...
  • Little do people know predators are lurking in the dark, recording their every move from hidden cameras; you would never even expect where these cameras are hiding.
  • Here's how to check for hidden cameras:
    This is a list of the most common places to locate indoor hidden cameras:

Powerbridge Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Retrieved on: 
Sunday, January 16, 2022 - 8:00am

This press release is issued pursuant to NASDAQ Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.

Key Points: 
  • This press release is issued pursuant to NASDAQ Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.
  • NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
  • Based on the closing bid price of the Company's ordinary shares for the 30 consecutive business days from November 29, 2021 to January 11, 2022, the Company no longer meets the minimum bid price requirement.
  • To regain compliance, the Company's ordinary shares must have a closing bid price of at least US$1.00 for a minimum of 10 consecutive trading days.

Phoenix New Media Receives Notice Regarding NYSE Continued Listing Standard

Retrieved on: 
Friday, January 14, 2022 - 10:00pm

This press release is issued within the 30-day period following receipt of such notice as required under the NYSE rules.

Key Points: 
  • This press release is issued within the 30-day period following receipt of such notice as required under the NYSE rules.
  • The Company has six months ("the Cure Period") following receipt of the notice to regain compliance with the minimum share price requirement.
  • During the Cure Period, the Company's ADSs will continue to be listed and traded on the NYSE, subject to its compliance with other NYSE continued listing standards and other rights of the NYSE to delist the ADSs.
  • Phoenix New Media Limited (NYSE: FENG) is a leading new media company providing premium content on an integrated Internet platform, including PC and mobile, in China.

CooTek Announces Receipt of NYSE Non-Compliance Letter

Retrieved on: 
Friday, January 14, 2022 - 10:00pm

Accordingly, the Company is now subject to the procedures as set forth in Sections 801 and 802 of the NYSE Listed Company Manual, and is required to respond within 90 days of the Letter with a business plan that demonstrates compliance with the continued listing standard within 18 months of receipt of the Letter.

Key Points: 
  • Accordingly, the Company is now subject to the procedures as set forth in Sections 801 and 802 of the NYSE Listed Company Manual, and is required to respond within 90 days of the Letter with a business plan that demonstrates compliance with the continued listing standard within 18 months of receipt of the Letter.
  • The business plan will be reviewed for final disposition by the Listings Operations Committee of the NYSE.
  • To address this issue, CooTek intends to comply with the applicable procedures and is still considering its options to regain compliance.
  • CooTek is a mobile internet company with a global vision that offers content-rich mobile applications, focusing on three categories: online literature, scenario-based content apps and mobile games.

NRx Responds to Relief’s Allegations of January 14, 2022

Retrieved on: 
Friday, January 14, 2022 - 7:34pm

RADNOR, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals(NASDAQ:NRXP), a clinical-stage biopharmaceutical company, responded to todays press release issued by Relief Therapeutics.

Key Points: 
  • RADNOR, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals(NASDAQ:NRXP), a clinical-stage biopharmaceutical company, responded to todays press release issued by Relief Therapeutics.
  • Relief has accused NRx and its CEO of issuing false and misleading statements about the past actions of Reliefs Board and Management.
  • At no time has NRx accused any member of Reliefs board of current or past criminal activity.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.

Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

Retrieved on: 
Friday, January 14, 2022 - 4:45pm

Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019.

Key Points: 
  • Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019.
  • According to Research and Markets, the global breast cancer drugs market is expected to grow to $19.49 billion by 2025 at a CAGR of 7.1%.
  • Within its Breast Cancer Program so far, Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- breast cancer patients treated with pelareorep in IND-213as seen from study results delivered in 2017.
  • The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute ofNew Jerseyand theOhio State UniversityComprehensive Cancer Center.

Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

Retrieved on: 
Friday, January 14, 2022 - 4:45pm

VANCOUVER, BC, Jan. 14, 2022 /PRNewswire/ -- USA News Group - Cancer cases are on the rise, according to a new study comparing the number of cancer diagnoses globally in 2010 and 2019. Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019. According to Research and Markets, the global breast cancer drugs market is expected to grow to $19.49 billion by 2025 at a CAGR of 7.1%. Among the biotech developers working into 2022 on new treatments for breast cancer are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Roche Holding AG (OTC:RHHBY), Pfizer Inc. (NYSE:PFE), Incyte Corporation (NASDAQ:INCY) and AstraZeneca PLC (NASDAQ:AZN).

Key Points: 
  • Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019.
  • According to Research and Markets, the global breast cancer drugs market is expected to grow to $19.49 billion by 2025 at a CAGR of 7.1%.
  • Within its Breast Cancer Program so far, Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- breast cancer patients treated with pelareorep in IND-213as seen from study results delivered in 2017.
  • The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute ofNew Jerseyand theOhio State UniversityComprehensive Cancer Center.

Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Owlet, Inc.  

Retrieved on: 
Friday, January 14, 2022 - 3:37pm

The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Owlet, Inc. (Owlet) ( NYSE: OWLT ) f/k/a Sandbridge Acquisition Corp. (NYSE: SBG) (Sandbridge).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Owlet, Inc. (Owlet) ( NYSE: OWLT ) f/k/a Sandbridge Acquisition Corp. (NYSE: SBG) (Sandbridge).
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.

Blender Bites Announces Approval of Forward Share Split

Retrieved on: 
Friday, January 14, 2022 - 12:00am

VANCOUVER, British Columbia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Blender Bites Ltd. (the Company, Blender Bites or Blender), (CSE: BITE, FWB: JL4, WKN: A3C3Y2), a Canadian company involved in the development and marketing of a line of premium, organic and plant-based pre-portioned frozen functional foods, announces that the Canadian Securities Exchange (the CSE) has approved a forward share split (the Forward Split) in which existing shareholders of the Company will receive 1.25 common shares in exchange for every existing common share of the Company, as previously announced on January 6, 2022.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Blender Bites Ltd. (the Company, Blender Bites or Blender), (CSE: BITE, FWB: JL4, WKN: A3C3Y2), a Canadian company involved in the development and marketing of a line of premium, organic and plant-based pre-portioned frozen functional foods, announces that the Canadian Securities Exchange (the CSE) has approved a forward share split (the Forward Split) in which existing shareholders of the Company will receive 1.25 common shares in exchange for every existing common share of the Company, as previously announced on January 6, 2022.
  • All shareholders of record on January 19, 2022, will be entitled to the Forward Split.
  • The new CUISP number assigned to the Companys shares following the Forward Split is 09353K208 (ISIN: CA09353K2083).
  • Following completion of the Forward Split, the Company will have approximately 36,978,280 common shares outstanding.